Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 5887 |
| PDBID: | 8CML |
| Chains: | A_B |
| Organism: | Lama glama, Homo sapiens |
| Method: | EM |
| Resolution (Å): | 3.60 |
| Reference: | 10.1016/j.jbc.2023.104956 |
| Antibody | |
| Antibody: | UNbC5-2 VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Human complement C5 alpha chain |
| Antigen mutation: | No |
| Durg Target: | P01031; P01031; |
Sequence information
Antibody
Chain: A
Mutation: NULL
| >8CML_A|Chain A|Nanobody UNbC5-2|Lama glama (9844) MEVQLVESGGGLVQPGGSLRLSCAASGRTFSTNTMGWFRQAPGQEREFVALISGNGRILDYSDSAKGRFTISRDNAKNTVYLQMNSLKPEDTGVYFCAAEFRGRTLASYWGQGTQVTVSSAAASGSLEQKLISEEDLNGAAHHHHHHGAA |
Antigen
Chain: B
Mutation: NULL
| >8CML_B|Chain C[auth B]|Complement C5 alpha chain|Homo sapiens (9606) TLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLVPRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTVLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFPYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFYVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTAFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEARENSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDKTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLNLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHKGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLKIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLKALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHRPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYAYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIMGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: GLU1 VAL2 ARG27 THR28 SER30 THR31 ASN32 THR33 LEU50 SER52 ASN54 ARG56 ILE57 ASP59 GLU99 PHE100 ARG101 GLY102 ARG103 LEU105 TYR108 B: GLU1026 THR1027 ASN1090 LYS1091 TYR1092 GLU1094 GLN1097 ARG1153 PHE1156 ASP1157 ILE1158 CYS1159 PRO1160 LEU1161 VAL1162 ASP1165 LEU1168 LEU1197 GLY1198 ASP1199 LYS1200 LYS1305 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
